Why the study?
New 2019 Cirrhotic Cardiomyopathy Consortium criteria altered diagnostic thresholds for systolic and diastolic dysfunction compared to prior recommendations, prompting evaluation of cirrhotic cardiomyopathy prevalence across different diagnostic criteria.
How does the prevalence of cirrhotic cardiomyopathy vary when applying the 2019 CCC criteria compared to the 2005 Montreal and 2009 ASE/EACVI criteria in cirrhotic patients?
Population
122 patients with cirrhosis without other structural heart disease, hypertension, portal vein thrombosis, HCC, or TIPS
Comparison
2019 CCC criteria vs 2005 Montreal recommendations vs ASE/EACVI criteria
Authors
Loading...
Should not yet change CCM diagnostic practice; leaves open whether 2019 criteria better predict clinically relevant outcomes.
How does the prevalence of cirrhotic cardiomyopathy vary when applying the 2019 CCC criteria compared to the 2005 Montreal and 2009 ASE/EACVI criteria in cirrhotic patients?
The 2019 CCC criteria diagnose cirrhotic cardiomyopathy in approximately 60% of cirrhotic patients, with a notably higher prevalence of systolic dysfunction compared to older criteria.
Razpotnik et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: